The objective of this study was to compare indinavir peak plasma (Cmax) values after administration of indinavir/ritonavir 800/100 mg on an empty stomach or with food. High indinavir Cmax values have been associated with indinavir-related nephrotoxicity.
Methods
This was an open-label, randomized, two-treatment, two-period, cross-over pharmacokinetic study performed at steady state. HIV-infected patients who had been using indinavir/ritonavir 800/100 mg twice daily for at least 4 weeks were randomized to take this combination with a light breakfast (two filled rolls and 130 ml of fluid) on a first study day, and without food on a second day, or in the reverse order. The pharmacokinetics of indinavir and ritonavir were assessed after plasma and urine sampling during 12 h.
Results
Data for nine patients were evaluated. Administration of indinavir/ritonavir 800/100 mg on an empty stomach resulted in a higher indinavir Cmax [geometric mean (GM) ratio – fasting/fed and 95% confidence interval (CI): 1.28 (1.08–1.52), P=0.01] and a trend to a shorter indinavir tmax (P=0.07) compared to administration with food. The mode of administration of indinavir/ritonavir did not affect plasma indinavir Cmin and AUC values, parameters that have been associated with the antiviral efficacy of indinavir, nor the urinary excretion of indinavir.
Conclusions
Administration of indinavir/ritonavir 800/100 mg on an empty stomach results in a higher indinavir Cmax compared to ingestion with a light meal. Stated the other way round, intake with a light meal reduces indinavir Cmax, which probably reflects a food-induced delay in the absorption of indinavir. It is recommended to administer indinavir/ritonavir 800/100 mg with food, as a possible means to prevent indinavir-related nephrotoxicity in patients who start or continue with this regimen.
References
1.
van HeeswijkR.P.G., VeldkampA.I., MulderJ.W., MeenhorstP.L., LangeJ.M.A., BeijnenJ.H., & HoetelmansR.M.W.Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience. Antiviral Therapy2002; 6: 201–229.
2.
PloskerG.L., & NobleS.Indinavir: a review of its use in the management of HIV infection. Drugs1999; 58: 1165–1203.
3.
SaahA.J., WinchellG.A., NesslyM.L., SeniukM.A., RhodesR.R., & DeutschP.J.Pharmacokinetic profile and tolerability of indinavir–ritonavir combinations in healthy volunteers. Antimicrobial Agents & Chemotherapy2001; 45: 2710–2715.
4.
Heeswijk vanR.P.G., VeldkampA.I., HoetelmansR.M.W., MulderJ.W., SchreijG., HsuA., LangeJ.M.A., BeijnenJ.H., & MeenhorstP.L.The steady-state pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals. AIDS1999; 13: F95–F99.
5.
WellingP.G.Effects of food on drug absorption. Pharmacology & Therapeutics1989; 43: 425–441.
6.
WilliamsL., HillD.P.Jr., DavisJ.A., & LowenthalD.T.The influence of food on the absorption and metabolism of drugs: an update. European Journal of Drug Metabolism & Pharmacokinetics1996; 21: 201–211.
7.
FleisherD., LiC., ZhouY., PaoL.H., & KarimA.Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical Pharmacokinetics1999; 36: 233–254.
8.
DielemanJ.P., SalahuddinS., HsuY.S., BurgerD.M., GyssensI.C., SturkenboomM.C.J.M., StrickerB.H.C.h, & KokD.J.Indinavir crystallization around the loop of Henle: experimental evidence. Journal of Acquired Immune Deficiency Syndromes2001; 28: 9–13.
9.
DielemanJ.P., GyssensI.C., Ende vdM.E., Marie deS., BurgerD.M.Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS1999; 13: 473–478.
10.
CasadoJ.L., MorenoA., SabidoR., Marti-BeldaP., AntelaA., DrondaF., Perez-EliazM.J., & MorenoS.A clinical study of the combination of 100 mg ritonavir plus 800 mg indinavir as salvage therapy: influence of increased plasma drug levels in the rate of response. HIV Clinical Trials2000; 1: 13–19.
11.
GattiG., di BiagioA., de PascalisC.R., BassettiM., VellaS., & BassettiD.The relationship between systemic exposure to indinavir and response (virologic efficacy and renal toxicity).41th Interscience Conference on Antimicrobial Agents & Chemotherapy, Chicago, Ill., USA, 14–18 December 2001; Abstract I-1732.
12.
DielemanJ.P., van RossumA.M., StrickerB.C.H., SturkenboomM.C.J.M., de GrootR., TelgtD., BlokW.L., BurgerD.M., BlijenbergB.G., ZietseR., & GyssensI.C.Persistent leukocyturia and loss of renal function in a prospectively monitored cohort of HIV-infected patients treated with indinavir. Journal of Acquired Immune Deficiency Syndromes2003; 32: 135–142.
13.
WorkmanC., WhittakerW., DyerW., & SullivanJ.Combining ritonavir (RTV) and indinavir (IDV) decreases IDV-associated urinary and renal adverse events (AES).7th European Conference on Clinical Aspects & Treatment of HIV-Infection, Lisbon, Portugal, 23–27 October 1999; Abstract 116.
14.
PadbergJ., FritscheL., BergmannF., SchurmannD., & SuttorpN.Nephropathy and renal colic in patients treated with indinavir, ritonavir + indinavir or ritonavir + saquinavir. AIDS1999; 13: 2173–2174.
15.
LichterfeldM., NischalkeH.D., BergmannF., WieselW., RiekeA., TheisenA., FätkenheuerG., OetteM., CarlsH., FenskeS., NadlerM., KnechtenH., WasmuthJ.C., & RockstrohJ.K.Long-term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy. HIV Medicine2002; 3: 37–43.
16.
VoigtE., WickesbergA., WasmuthJ.C., GuteP., LocherL., SalzbergerB., WohrmannA., AdamA., WeitnerL., & RockstrohJ.K.First-line ritonavir/indinavir 100/800 mg twice daily plus nucleoside reverse transcriptase inhibitors in a German multicentre study: 48-week results. HIV Medicine2002; 3: 277–282.
17.
BoydM., DuncombeC., RuxrungthamK., KhongphattanayothinM., HassinkE., SrasuebkolP., SangkoteJ., ReissP., StekM., LangeJ.M.A., CooperD.A., & PhanupakP.Indinavir TID vs indinavir/ritonavir BID in combination with AZT/3TC for HIV Infection in nucleoside pretreated patients: HIV-NAT 005 76 week follow-up.9th Conference on Retroviruses & Opportunistic Infections, Seattle, Wash., USA, 24–28 February 2002; Abstract 422-W.
18.
YoungB., FischlM.A., WilsonH.M., FinnT.S., JensenE.H., DiNubileM.J., & ZeldinR.K.Open-label study of a twice-daily indinavir 800-mg/ritonavir 100-mg regimen in protease inhibitor-naive HIV-infected adults. Journal of Acquired Immune Deficiency Syndromes2002; 31: 478–482.
19.
HugenP.W.H., Verwey-van WissenC.P.W.G.M, BurgerD.M., WuisE.W., KoopmansP.P., & HeksterY.A.Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography. Journal of Chromatography. B, Biomedical Sciences & Applications.1999; 727: 139–149.
20.
AarnoutseR.E., GrintjesK.J., TelgtD.S., StekM.Jr., HugenP.W.H., ReissP., KoopmansP.P., HeksterY.A., & BurgerD.M.The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers. Clinical Pharmacology & Therapeutics2002; 71: 57–67.
21.
Chapter 2.Compartmental and noncompartmental pharmacokinetics. In Biopharmaceutics & Clinical Pharmacokinetics, 4th edn, 1991; pp 14–23. Edited by GibaldiM.Philadelphia, London: Lea & Febiger.
22.
AcostaE.P., KakudaT.N., BrundageR.C., AndersonP.L., & FletcherC.V.Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors. Clinical Infectious Diseases2000; 30(Suppl. 2): S151–S159.
23.
BurgerD.M., HugenP.W.H., AarnoutseR.E., DielemanJ.P., PrinsJ.M., van der PollT., ten VeenJ.H., MulderJ.W., MeenhorstP.L., BlokW.L., van der MeerJ.T.M., ReissP., & LangeJ.M.A.A retrospective, cohort-based survey of patients using twice daily indinavir + ritonavir combinations: pharmacokinetics, safety and efficacy. Journal of Acquired Immune Deficiency Syndromes2001; 26: 218–224.
24.
YehK.C., DeutschP., HaddixH., HesneyM., HoaglandV., JuW.D., JusticeS.J., OsborneB., SterrettA.T., StoneJ.A., WoolfE., & WaldmanS.Single-dose pharmacokinetics of indinavir and the effect of food. Antimicrobial Agents & Chemotherapy1998; 42: 332–338.
25.
LinJ.H.Role of pharmacokinetics in the discovery and development of indinavir. Advanced Drug Delivery Reviews1999; 39: 33–49.
26.
HsuA., GrannemanG.R., CaoG., CarothersL., JapourA., El-ShourbagyT., DennisS., BergJ., ErdmanK., LeonardJ.M., & SunE.Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrobial Agents & Chemotherapy1998; 42: 2784–2791.
27.
ShulmanN., ZolopaA., HavlirD., HsuA., RenzC., BollerS., JiangP., RodeR., GallantJ., RaceE., KempfD.J., & SunE.Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia. Antimicrobial Agents & Chemotherapy2002; 46: 3907–3916.
28.
GhosnJ., LamotteC., Ait-MohandH., WirdenM., AgherR., SchneiderL., BricaireF., DuvivierC., CalvezV., PeytavinG., & KatlamaC.Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients. AIDS2003; 17: 209–214.
29.
WasmuthJ.C., La PorteC.J.L., SchneiderK., VoigtE., BurgerD.M., & RockstrohJ.K.Combination of reduced dose indinavir and ritonavir in healthy volunteers.6th International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 17–21 November 2002; Abstract P182.
30.
BurgerD., HugenP., ReissP., GyssensI., SchneiderM., KroonF., SchreijG., BrinkmanK., RichterC., PrinsJ., AarnoutseR., & LangeJ.Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS2003; 17: 1157–1165.
